CY1124203T1 - Μεθοδοι και συνθεσεις για την ειδικη αναστολη της οξειδασης του γλυκολικου (ηαο1) απο το δικλωνο rna - Google Patents

Μεθοδοι και συνθεσεις για την ειδικη αναστολη της οξειδασης του γλυκολικου (ηαο1) απο το δικλωνο rna

Info

Publication number
CY1124203T1
CY1124203T1 CY20211100465T CY211100465T CY1124203T1 CY 1124203 T1 CY1124203 T1 CY 1124203T1 CY 20211100465 T CY20211100465 T CY 20211100465T CY 211100465 T CY211100465 T CY 211100465T CY 1124203 T1 CY1124203 T1 CY 1124203T1
Authority
CY
Cyprus
Prior art keywords
hao1
compositions
methods
double
stranded rna
Prior art date
Application number
CY20211100465T
Other languages
Greek (el)
English (en)
Inventor
Bob D. Brown
Henryk T. Dudek
Original Assignee
Dicerna Pharmaceuticals, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dicerna Pharmaceuticals, Inc filed Critical Dicerna Pharmaceuticals, Inc
Publication of CY1124203T1 publication Critical patent/CY1124203T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
    • C12Y101/03015—(S)-2-Hydroxy-acid oxidase (1.1.3.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CY20211100465T 2013-12-27 2021-05-28 Μεθοδοι και συνθεσεις για την ειδικη αναστολη της οξειδασης του γλυκολικου (ηαο1) απο το δικλωνο rna CY1124203T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361921181P 2013-12-27 2013-12-27
US201461937838P 2014-02-10 2014-02-10
EP14874374.3A EP3087184B1 (en) 2013-12-27 2014-12-26 Methods and compositions for the specific inhibition of glycolate oxidase (hao1) by double-stranded rna
PCT/US2014/072410 WO2015100436A1 (en) 2013-12-27 2014-12-26 Methods and compositions for the specific inhibition of glycolate oxidase (hao1) by double-stranded rna

Publications (1)

Publication Number Publication Date
CY1124203T1 true CY1124203T1 (el) 2021-12-31

Family

ID=53479713

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20211100465T CY1124203T1 (el) 2013-12-27 2021-05-28 Μεθοδοι και συνθεσεις για την ειδικη αναστολη της οξειδασης του γλυκολικου (ηαο1) απο το δικλωνο rna
CY2021022C CY2021022I1 (el) 2013-12-27 2021-08-26 Μεθοδοι και συνθεσεις για την ειδικη αναστολη της οξειδασης του γλυκολικου (ηαο1) απο το δικλωνο rna

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2021022C CY2021022I1 (el) 2013-12-27 2021-08-26 Μεθοδοι και συνθεσεις για την ειδικη αναστολη της οξειδασης του γλυκολικου (ηαο1) απο το δικλωνο rna

Country Status (21)

Country Link
US (7) US9701966B2 (enExample)
EP (3) EP3087184B1 (enExample)
JP (2) JP6886818B2 (enExample)
AU (2) AU2014369850B2 (enExample)
CA (1) CA2935220A1 (enExample)
CY (2) CY1124203T1 (enExample)
DK (2) DK3581654T3 (enExample)
ES (2) ES2875558T3 (enExample)
FI (1) FIC20210025I1 (enExample)
FR (1) FR21C1044I2 (enExample)
HR (1) HRP20210612T1 (enExample)
HU (2) HUE055470T2 (enExample)
LT (2) LT3581654T (enExample)
LU (1) LUC00218I2 (enExample)
NO (1) NO2021038I1 (enExample)
PL (1) PL3581654T3 (enExample)
PT (1) PT3581654T (enExample)
RS (1) RS61892B1 (enExample)
SI (1) SI3581654T1 (enExample)
SM (1) SMT202100325T1 (enExample)
WO (1) WO2015100436A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
SI3581654T1 (sl) * 2013-12-27 2021-08-31 Dicerna Pharmaceuticals, Inc. Postopki in sestavki za specifično inhibicijo glikolat-oksidaze (HA01) z dvoverižno RNA
TWI864340B (zh) * 2014-10-10 2024-12-01 美商艾爾妮蘭製藥公司 用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法
WO2016205323A1 (en) * 2015-06-18 2016-12-22 Alnylam Pharmaceuticals, Inc. Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
EP3522719A1 (en) * 2016-10-05 2019-08-14 Syngenta Participations AG Methods of preserving the biological activity of ribonucleic acids
US20180193270A1 (en) 2016-11-29 2018-07-12 PureTech Health LLC Exosomes for delivery of therapeutic agents
AU2018301829B2 (en) 2017-07-13 2024-08-01 Alnylam Pharmaceuticals, Inc. Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase) gene expression
MX2021001070A (es) * 2018-07-31 2021-05-27 Intellia Therapeutics Inc Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1).
EP3898661A1 (en) * 2018-12-21 2021-10-27 Precision BioSciences, Inc. Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria
WO2021086874A1 (en) 2019-11-01 2021-05-06 GyanRx Sciences, Inc. Heterocyclic carboxylate compounds as glycolate oxidase inhibitors
WO2021237067A1 (en) * 2020-05-22 2021-11-25 President And Fellows Of Harvard College Interferon- inducing oligonucleotide duplexes and methods of use
KR20250099412A (ko) 2020-11-12 2025-07-01 프리시젼 바이오사이언시스 인코포레이티드 디스트로핀 유전자 내의 인식 서열에 대해 특이성을 갖는 조작된 메가뉴클레아제
EP4043018A1 (en) 2021-02-10 2022-08-17 Charité - Universitätsmedizin Berlin Composition and method for reducing oxalate levels in patients receiving maintenance dialysis
KR20240034746A (ko) * 2021-06-04 2024-03-14 아버 바이오테크놀로지스, 인크. 하이드록시산 산화효소 1(hao1)을 표적으로 하는 rna 가이드를 포함하는 유전자 편집 시스템 및 이의 용도
JP2024528659A (ja) * 2021-07-19 2024-07-30 アルナイラム ファーマシューティカルズ, インコーポレイテッド 非原発性高シュウ酸尿症疾患または障害を有するまたは発症するリスクがある対象を治療するための方法および組成物
TW202430637A (zh) 2022-11-16 2024-08-01 美商戴瑟納製藥股份有限公司 Stat3靶向性寡核苷酸及其用途
CN117041337A (zh) * 2023-08-14 2023-11-10 中国电信股份有限公司技术创新中心 网络流量的处理方法、系统以及risc装置
EP4725949A1 (en) * 2024-10-08 2026-04-15 BioSpring Gesellschaft für Biotechnologie mbH Improved solid-phase phosphoramidite-synthesis of long oligonucleotide molecules

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US513207A (en) 1894-01-23 Rail-brake
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
AU649074B2 (en) 1990-10-12 1994-05-12 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Modified ribozymes
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
US6469158B1 (en) 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5804683A (en) 1992-05-14 1998-09-08 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA with alkylamine
US5977343A (en) 1992-05-14 1999-11-02 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
EP1253199A1 (en) 1993-09-02 2002-10-30 Ribozyme Pharmaceuticals, Inc. Abasic moieties containing enzymatic nucleic acids
US5889136A (en) 1995-06-09 1999-03-30 The Regents Of The University Of Colorado Orthoester protecting groups in RNA synthesis
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US6218108B1 (en) 1997-05-16 2001-04-17 Research Corporation Technologies, Inc. Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor
US6248878B1 (en) 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
US6111086A (en) 1998-02-27 2000-08-29 Scaringe; Stephen A. Orthoester protecting groups
US7678897B2 (en) * 2002-02-20 2010-03-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
EP2305813A3 (en) 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
US9879266B2 (en) * 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
CA2559955C (en) 2004-03-15 2016-02-16 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
CA2566286A1 (en) 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
US20080213891A1 (en) 2004-07-21 2008-09-04 Alnylam Pharmaceuticals, Inc. RNAi Agents Comprising Universal Nucleobases
WO2007030167A1 (en) 2005-09-02 2007-03-15 Nastech Pharmaceutical Company Inc. Modification of double-stranded ribonucleic acid molecules
US8178503B2 (en) * 2006-03-03 2012-05-15 International Business Machines Corporation Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes
JP4644619B2 (ja) 2006-03-27 2011-03-02 富士通株式会社 基地局装置、端末および帯域制御方法
DE102007021853A1 (de) 2007-05-10 2008-11-13 Norma Germany Gmbh Steckkupplung und Stutzen für eine Steckkupplung
US20110288147A1 (en) 2008-09-22 2011-11-24 Bob Dale Brown Compositions and methods for the specific inhibition of gene expression by DSRNA containing a tetraloop
CN101752443B (zh) 2008-12-08 2012-06-20 鸿富锦精密工业(深圳)有限公司 光伏电池
KR20110110776A (ko) * 2008-12-18 2011-10-07 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
WO2010093788A2 (en) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Multiplex dicer substrate rna interference molecules having joining sequences
EP2756845B1 (en) * 2009-04-03 2017-03-15 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
WO2010135682A1 (en) * 2009-05-21 2010-11-25 Institute For Systems Biology New biomarkers for liver injury
UA118649C2 (uk) 2011-11-18 2019-02-25 Елнілем Фармасьютікалз, Інк. ДВОЛАНЦЮГОВИЙ ЗАСІБ ДЛЯ PHKі ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ЕКСПРЕСІЇ ТРАНСТИРЕТИНУ (TTR)
US9133461B2 (en) * 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
SI3581654T1 (sl) * 2013-12-27 2021-08-31 Dicerna Pharmaceuticals, Inc. Postopki in sestavki za specifično inhibicijo glikolat-oksidaze (HA01) z dvoverižno RNA
TWI864340B (zh) * 2014-10-10 2024-12-01 美商艾爾妮蘭製藥公司 用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法

Also Published As

Publication number Publication date
FR21C1044I2 (fr) 2022-09-23
EP3581654B1 (en) 2021-03-31
EP3087184A1 (en) 2016-11-02
JP2020036603A (ja) 2020-03-12
SMT202100325T1 (it) 2021-07-12
FIC20210025I1 (fi) 2021-08-25
CY2021022I2 (el) 2021-12-31
EP3581654A1 (en) 2019-12-18
AU2021201953A1 (en) 2021-04-29
RS61892B1 (sr) 2021-06-30
EP3087184A4 (en) 2017-08-16
HUS2100041I1 (hu) 2021-10-28
US10435692B2 (en) 2019-10-08
JP7109416B2 (ja) 2022-07-29
US20150184160A1 (en) 2015-07-02
US20180291379A1 (en) 2018-10-11
US9701966B2 (en) 2017-07-11
JP6886818B2 (ja) 2021-06-16
CA2935220A1 (en) 2015-07-02
HUE055470T2 (hu) 2021-11-29
DK3087184T3 (da) 2019-07-29
FR21C1044I1 (enExample) 2021-11-19
PL3581654T3 (pl) 2021-09-13
US20200002705A1 (en) 2020-01-02
ES2875558T3 (es) 2021-11-10
ES2749855T3 (es) 2020-03-24
LTPA2021008I1 (enExample) 2021-09-27
EP3087184B1 (en) 2019-07-03
EP3892727A1 (en) 2021-10-13
AU2014369850A1 (en) 2016-07-14
US20170306333A1 (en) 2017-10-26
US10487330B2 (en) 2019-11-26
NO2021038I1 (no) 2021-09-16
US20190211340A1 (en) 2019-07-11
LTC3581654I2 (enExample) 2023-07-10
HRP20210612T1 (hr) 2021-08-20
CY2021022I1 (el) 2021-12-31
LUC00218I2 (enExample) 2022-10-07
US10465195B2 (en) 2019-11-05
US11873493B2 (en) 2024-01-16
US20210230604A1 (en) 2021-07-29
JP2017502668A (ja) 2017-01-26
LT3581654T (lt) 2021-06-25
US11060093B2 (en) 2021-07-13
DK3581654T3 (da) 2021-04-26
AU2014369850B2 (en) 2021-04-08
WO2015100436A1 (en) 2015-07-02
PT3581654T (pt) 2021-06-02
US9828606B2 (en) 2017-11-28
US20190194665A1 (en) 2019-06-27
SI3581654T1 (sl) 2021-08-31

Similar Documents

Publication Publication Date Title
CY1122975T1 (el) Συνθεσεις και μεθοδοι για την αναστολη της εκφρασης του γονιδιου alas1
CY1122159T1 (el) Συνθεσεις irna του γονιδιου serpina1 και μεθοδοι χρησης τους
CY1124845T1 (el) Μεθοδοι παροχης μονοκλωνου rna
CY1125029T1 (el) Τροποποιημενοι νουκλεοζιτες, νουκλεοτιδια, και νουκλεϊκα οξεα και χρησεις αυτων
CY1125236T1 (el) Rna τροποποιημενου ακρου
CY1120289T1 (el) Συνθεσεις irna συστατικου c5 του συμπληρωματος και μεθοδοι χρησης αυτων
CY1119491T1 (el) Συνθεσεις και μεθοδοι για την αναστολη της εκφρασης του γονιδιου alas1
CY1124670T1 (el) Μεθοδοι και συνθεσεις για την παροχη mrna κωδικοποιημενων αντισωματων
CY1123693T1 (el) Παραγοντες rnai, συνθεσεις και μεθοδοι χρησης αυτων για τη θεραπευτικη αγωγη σχετιζομενων με τρανσθυρετινη (ttr) ασθενειων
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
CY2021022I2 (el) Μεθοδοι και συνθεσεις για την ειδικη αναστολη της οξειδασης του γλυκολικου (ηαο1) απο το δικλωνο rna
CO2018006590A2 (es) Métodos y composiciones para el tratamiento de un trastorno asociado a serpinc1
MX2021006053A (es) Composiciones de angiotensinogeno (agt) arni y metodos de uso de las mismas.
EA201792626A1 (ru) Композиции и способы для ингибирования экспрессии транстиретина
MX386418B (es) Composicion acida que comprende una ficocianina.
WO2015003113A3 (en) Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded rna
EA201692104A1 (ru) Ингибиторы асс и их применения
BR112016005957A2 (pt) detecção de alvo multiaptâmero
EA201591961A1 (ru) Ингибиторы акк и их применение
EA201690098A1 (ru) Конденсированные трициклические соединения мочевины в качестве ингибиторов киназы raf и/или димера киназы raf
EA201591959A1 (ru) Ингибиторы акк и их применение
EA201591960A1 (ru) Ингибиторы акк и их применение
UA116920C2 (uk) Інгібітори fgfr4
MX336875B (es) Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk).
CY1125447T1 (el) Ειδικες πρωτεινες για baff και b7rp1 και χρησεις αυτων